Zura Bio Limited (ZURA) — Financial statements
Income statement, balance sheet, and cash flow for Zura Bio Limited — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 42↑72.5% | 24↓44.5% | 44↑85.7% | 24 | 0.00 | |
| General & Administrative Expenses | 33↑7.7% | 31↑65.2% | 19↑436.7% | 3 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 33↑7.7% | 31↑65.2% | 19↑436.7% | 3↑218.0% | 1 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 75↑36.3% | 55↓11.9% | 63↑130.6% | 27↑2387.4% | 1 | |
| Total Costs & Expenses | 75↑36.3% | 55↓11.9% | 63↑130.6% | 27↑2387.4% | 1 | |
| Operating Results | ||||||
| Operating Income | -75↓36.3% | -55↑11.9% | -63↓130.6% | -27↓2387.4% | -1 | |
| Depreciation & Amortization | 0.05↑444.4% | 0.01 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -75↓36.3% | -55↑11.9% | -63↓130.6% | -27↓422.7% | 8 | |
| EBIT | -75↓36.3% | -55↑11.9% | -63↓130.6% | -27↓422.7% | 8 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓20.8% | 8↑265.9% | 2↑383408.8% | 0.00↓97.6% | 0.02 | |
| Interest Income | 6↓20.8% | 8↑265.9% | 2↑383408.8% | 0.00↓97.6% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -10 | |
| Other Income / Expenses | 7↑136.8% | 3↑34.3% | 2↑1313.5% | -0.17↓101.8% | 10 | |
| Income Before Tax | -69↓31.0% | -52↑13.5% | -61↓121.6% | -27↓424.7% | 8 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -69↓31.0% | -52↑13.5% | -61↓121.6% | -27↓424.7% | 8 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -69↓31.0% | -52↑13.2% | -60↓134.5% | -26↓405.8% | 8 | |
| Bottom-Line Net Income | -99↓118.9% | -45↑34.5% | -69↓113.8% | -32↓484.8% | 8 | |
| EPS (Basic) | -1.06↓76.7% | -0.60↑71.3% | -2.09↓1095.2% | 0.21↓47.5% | 0.40 | |
| EPS (Diluted) | -1.06↓76.7% | -0.60↑71.3% | -2.09↓1095.2% | 0.21↓47.5% | 0.40 | |
| Weighted Average Shares | 94↑25.4% | 75↑127.0% | 33↑91.7% | 17↑0.0% | 17 | |
| Weighted Average Diluted Shares | 94↑25.4% | 75↑127.0% | 33↑91.7% | 17↑0.0% | 17 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.